Keijo A. Väkiparta
Président chez UniCrop Oy
Profil
Keijo A.
Väkiparta is currently the Chairman at UniCrop Oy.
Previously, he served as Chairman at Juvantia Pharma Oy and as Director at Genizon Biosciences, Inc., Ipsat Therapies Oy, and Takara Bio Europe AB.
Väkiparta holds a Master's in Business Administration from the University of Helsinki, which he earned in 1972, and a graduate degree from the same institution, which he earned in 1979.
Postes actifs de Keijo A. Väkiparta
Sociétés | Poste | Début |
---|---|---|
UniCrop Oy
UniCrop Oy Pharmaceuticals: MajorHealth Technology UniCrop Oy develops sprouting technology for the production of therapeutic proteins. It develops prouting technology for the production of therapeutic proteins. It uses molecular biology technologies to develop new uses for plants. The company was founded by Kimmo Koivu and Viktor Kuvshinov in 1998 and is located in Helsinki, Finland. | Président | - |
Anciens postes connus de Keijo A. Väkiparta
Sociétés | Poste | Fin |
---|---|---|
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Directeur/Membre du Conseil | 30/05/2012 |
Ipsat Therapies Oy
Ipsat Therapies Oy Pharmaceuticals: MajorHealth Technology Ipsat Therapies Oy develops and manufactures antibiotics & drugs. Its products include penicillins, cephalosporins and carbapenems. The firm develops products for the prevention of antibiotic resistance, antibiotic-associated diarrhea and hospital associated infections. The company was founded in 2000 and is headquartered in Helsinki, Finland. | Directeur/Membre du Conseil | 31/01/2012 |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Directeur/Membre du Conseil | - |
Juvantia Pharma Oy
Juvantia Pharma Oy Miscellaneous Commercial ServicesCommercial Services Juvantia Pharma Oy discovers and develops pharmaceuticals and drugs. The firm develops products for the treatment of Parkinson's disease, depression and schizophrenia, vasoconstrictive disorders, fibro proliferative vasculopathies and chronic pain.The company was founded by Risto Arvo Sakari Lammintausta in 1997 and is headquartered in Turku, Finland. | Président | - |
Formation de Keijo A. Väkiparta
University of Helsinki | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 5 |
---|---|
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Health Technology |
Juvantia Pharma Oy
Juvantia Pharma Oy Miscellaneous Commercial ServicesCommercial Services Juvantia Pharma Oy discovers and develops pharmaceuticals and drugs. The firm develops products for the treatment of Parkinson's disease, depression and schizophrenia, vasoconstrictive disorders, fibro proliferative vasculopathies and chronic pain.The company was founded by Risto Arvo Sakari Lammintausta in 1997 and is headquartered in Turku, Finland. | Commercial Services |
Ipsat Therapies Oy
Ipsat Therapies Oy Pharmaceuticals: MajorHealth Technology Ipsat Therapies Oy develops and manufactures antibiotics & drugs. Its products include penicillins, cephalosporins and carbapenems. The firm develops products for the prevention of antibiotic resistance, antibiotic-associated diarrhea and hospital associated infections. The company was founded in 2000 and is headquartered in Helsinki, Finland. | Health Technology |
UniCrop Oy
UniCrop Oy Pharmaceuticals: MajorHealth Technology UniCrop Oy develops sprouting technology for the production of therapeutic proteins. It develops prouting technology for the production of therapeutic proteins. It uses molecular biology technologies to develop new uses for plants. The company was founded by Kimmo Koivu and Viktor Kuvshinov in 1998 and is located in Helsinki, Finland. | Health Technology |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Commercial Services |